Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville, Florida, USA.
Center for Drug Evaluation and Safety, University of Florida, Gainesville, Florida, USA.
Pharmacoepidemiol Drug Saf. 2022 Jan;31(1):100-104. doi: 10.1002/pds.5371. Epub 2021 Oct 21.
We evaluated the generalizability and accuracy of the IBM® MarketScan® Health Risk Assessment (HRA) data to assess its suitability as supplement to linked claims data.
We identified adult private insurance enrollees in the IBM® MarketScan® Commercial Claims & Encounters (CC&E) and HRA databases between 2012 and 2017. In the claims data, for each enrollee, we sampled the first calendar year with continuous enrollment indicating full capture of claims data and extracted linked HRA survey data if available. We compared HRA participants and non-participants considering demographics, prevalences of chronic conditions, and healthcare utilization. Including the subsample with HRA data only, we estimated the negative predictive value (NPV) of obesity and smoking reported in the HRA against diagnosis code in the claims data.
Between 2012 and 2017, 2 693 444 and 31 450 000 of HRA and non-HRA participants were included in the study, respectively. Chronic diseases were similarly distributed between the two populations, with hypertension and hyperlipidemia representing the highest prevalence difference (1.4%). The two samples showed similar healthcare utilization. The proportion of false-negatives for obesity and smoking information when relying on the HRA data compared to patients with positive diagnosis based on claims data was low (<1%). Prevalence estimates of both variables were similar to national estimates.
Our findings suggest that the overall HRA population may represent the overall claims population and HRA provides certain data elements with satisfactory accuracy.
我们评估了 IBM® MarketScan® 健康风险评估（HRA）数据的泛化能力和准确性，以评估其作为关联索赔数据补充的适宜性。
我们在 IBM® MarketScan® 商业索赔和遭遇（CC&E）和 HRA 数据库中确定了 2012 年至 2017 年期间的成年私人保险参保人。在索赔数据中，对于每一位参保人，我们采样了第一个连续参保的日历年，以充分捕获索赔数据，如果有可用的，我们还提取了关联的 HRA 调查数据。我们比较了 HRA 参与者和非参与者，考虑了人口统计学、慢性病的流行率和医疗保健利用情况。在仅包括 HRA 数据的子样本中，我们估计了 HRA 报告的肥胖和吸烟与索赔数据中诊断代码的阴性预测值（NPV）。
在 2012 年至 2017 年期间，HRA 和非 HRA 参与者分别有 2693444 人和 31450000 人纳入研究。两种人群的慢性病分布相似，高血压和高血脂的流行率差异最大（1.4%）。两个样本的医疗保健利用情况相似。与基于索赔数据的阳性诊断相比，依赖 HRA 数据时肥胖和吸烟信息的假阴性比例较低（<1%）。这两个变量的患病率估计与全国估计值相似。
我们的研究结果表明，总体 HRA 人群可能代表总体索赔人群，并且 HRA 提供了某些具有令人满意准确性的数据元素。
